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Abstract
Background: The role of cathepsins in the pathological progression of atherosclerotic lesions in ischem-
ic heart disease have been defined in detail more than numerous times. This investigation examined 
the platelet-specific biomarker trombospondin-1 (TSP-1) and platelet function ex vivo, and compared 
this with cathepsin S (Cat-S; a biomarker unrelated to platelet activation but also associated this with 
increased mortality risk) in patients with ST-segment elevation myocardial infarction (STEMI). 
Methods: The STEMI patients were divided into two groups depending on the degree of coronary vessel 
occlusion: those with closed (n = 90) and open culprit vessel (n = 40). Cat-S and TSP-1 were analyzed 
before, 1–3 days after and 3 months after percutanous coronary intervention (PCI).  
Results: During acute STEMI, plasma TSP-1 was significantly elevated in patients with closed cul-
prit lesions, but rapidly declined after PCI. In fact, TSP-1 after PCI was significantly lower inpatient 
samples compared to healthy individuals. In comparison, plasma Cat-S was significantly elevated both 
before and after PCI. In patients with closed culprit lesions, Cat-S was significantly higher compared 
to patients with open culprit lesions 3 months after PCI. Although troponin-I were higher (p < 0.01) in 
patients with closed culprit lesion, there was no correlation with Cat-S and TSP-1. 
Conclusions: Cat-S but not TSP-1 may be a useful risk biomarker in relation to the severity of 
STEMI. However, the causality of Cat-S as a predictor for long-term mortality in STEMI remains to 
be ascertained in future studies. (Cardiol J 2019; 26, 4: 385–393)
Key words: ST-segment elevation myocardial infarction, cathepsin S, percutaneous 
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Introduction
The role of cathepsins in the pathological 
progression of atherosclerotic lesions in ischemic 
heart disease have been described in detail more 
than a decade ago [1]. Cathepsin S (Cat-S) is one 
of the 11 family members, which are lysosomal 
proteases that participate in numerous physi-
ological systems [1, 2]. Cat-S is stable at a neutral 
or slightly alkaline pH, thus holding most of its 
activity extracellularly [3–5]. Additionally, it has 
more specific roles such as MHC class II antigen 
presentation, where it is important in the degrada-
tion of the invariant chain [6–8].
Cathepsins have been implicated in various 
physiologic and pathophysiologic cellular pro-
cesses, in which they act both as digestive and 
regulatory proteases [9]. The expression and 
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activity of these proteins are changed during vari-
ous inflammatory diseases, including rheumatoid 
arthritis, atherosclerosis, osteoporosis, abdominal 
aortic aneurysm and cancer [10]. Secretion of Cat-S 
is stimulated by pro-inflammatory interleukins 
such as IL-1b, and tumor necrosis factor as TNF-a 
[11, 12]. It was reported that normal cardiac tissues 
contained little or no Cat-S at all, but these proteins 
were richly expressed in cardiac myocytes, macro-
phages, intracoronary smooth muscle cells (SMCs) 
and endothelial cells, both in human and animals 
with heart failure and hypertension [12]. Numerous 
studies have recommended that the activity of Cat-S 
is amplified in the progression of atherosclerotic 
plaques towards plaque rupture [6, 13]. It has been 
reported that Cat-S has a powerful elastolytic and 
collagenolytic activity, and the lack of this enzyme 
activity apparently reduced the number of SMCs 
in the intima, and the disintegration of the elastic 
lamina atherosclerotic lesions [9]. This may explain 
that the interaction of Cat-S, released from SMC 
with extracellular matrix proteins, is involved 
in SMC migration and/or vascular remodeling 
a behavior that is likely to occur during the devel-
opment of the atherosclerotic plaque [9]. 
The human Cat-S transgenic heart in Cat-S 
knockout model/mice, is characterized by a re-
duction in overload has been shown to exhibit 
a decrease in overload-induced hypertrophic re-
sponses, apoptosis and fibrosis [9]. This suggests 
that the inflammatory processes that prevail during 
cardiac remodeling locally increase the presence 
of the active form of these cathepsins. The ability 
of cardiac myocytes and macrophages to use ca-
thepsins to degrade elastin and collagen support 
a function for these proteases in the cardiac wall in 
humans and animals [9]. The activation of platelet 
is fundamental in hemostasis and plays the most 
important role in initiating arterial thrombosis 
[14]. Platelet activation is also characterized by 
alpha-granule secretion leading to release of vari-
ous proteins such as thrombospondin-1 (TSP-1). 
This glycoprotein exerts many biological functions 
and probably contributes to the pathogenesis of 
atherosclerosis [15].
Based on previous experimental and clini-
cal studies, the aim of this study was to evaluate 
changes in Cat-S, TSP-1 and dysfunctional platelet 
responses ex vivo during ST-segment elevation 
myocardial infarction (STEMI) and to clarify if 
there were differences according to culprit vessel 
patency at angiography. The hypothesis was that 
complete occlusion of coronary blood flow (closed 
culprit lesion) may be associated with higher 
plasma levels of Cat-S and TSP-1, more severe 
myocardial tissue damage, and more pronounced 
dysfunctionality of platelet responses ex vivo. 
Methods
Patient material
Blood samples from 130 patients were col-
lected from the antecubital vein, into 3 mL sodium 
citrate vacutainer tubes, they were suffering from 
acute STEMI. Samples were collected  and 1–3 
days after and 3 months subsequent to percuta-
neous coronary intervention (PCI) at the Depart-
ment of Cardiology, Örebro University Hospital. 
Patients were categorized into two groups, one 
with patent culprit vessel (n = 40), while the 
other group had a closed culprit vessel (n = 90) 
before PCI. 
Control group 
Serving as a control group, 3 mL sodium 
citrate vacutainer tubes were also collected from 
(n = 40) healthy individual blood/plasma donors 
with blood pressure 135/85 mmHg or less, aged 
between 18 and 65 years, with no known risk fac-
tors for coronary artery disease (CAD) or clinical 
symptoms of any other organic disease. As per 
the selection criteria in each group, subjects were 
recruited with their informed consent. Informa-
tion regarding their demographic status, clinical 
history, and medication were noted down in detail. 
The study is approved by Regional Ethical Review 
Board in Uppsala, Dnr 2012/138.
Blood collection
Venous blood samples were collected and 
centrifuged at 2000 × g for 10 min prior to labora-
tory testing. The serum glucose, total cholesterol, 
low-density lipoprotein cholesterol (LDL-C), tri-
glyceride, and high-density lipoprotein cholesterol 
(HDL-C) levels were measured (Randox enzymatic 
kits and a Roche-Hitachi modular system). The 
blood samples were divided into aliquots and stored 
at –80°C until the analysis was performed. 
Baseline characteristics
Demographic data, cardiovascular risk factors, 
and medication use were retrieved from clinical 
records (Table 1). Hypertension was defined as 
systolic blood pressure > 140 mmHg, hypercho-
lesterolemia was evaluated from clinical records, 
diabetes was defined as use of insulin or oral hy-
poglycemic agents, and smoking was defined by 
whether patients had smoked or not.
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Plasma analyses
Troponin I was measured on an Architect 
8000 (Abbott Laboratories, Abbott Park, IL, USA) 
with high sensitivity (hs)-troponin I reagents from 
the same manufacturer. The assay had a limit of 
detection of 2 ng/L and a 10% coefficient of varia-
tion (CV) at 5 ng/L. The plasma samples stored at 
–80°C, were used for the estimation of levels Cat-S 
and platelet-specific TSP-1 by the commercially 
available enzyme-linked immunosorbent assay 
(ELISA) kits with monoclonal antibodies against 
each, according to the manufacturer’s instruc-
tions. The Cat-S (DY1183) and TSP-1 (DY3074) 
assays were performed with ELISA kits from R&D 
Systems (Minneapolis, MN, USA). The minimum 
detectable levels were 0.78 ng/mL for TSP-1 and 
15.6 pg/mL for Cat-S. The CV for the ELISAs was 
approximately 6%. The assays were performed 
blinded without knowledge of the clinical diagnosis.
Platelet aggregation
Platelet function analysis was performed us-
ing the Multiplate analyzer, a whole blood imped-
ance aggregometer (Roche/Dynabyte, Munich, 
Germany). Blood was collected into 4.5 mL tubes 
containing 25 µg/mL hirudin as an anticoagulant, 
according to the recommendations of the manufac-
turer. Analysis was performed within 3 h from sam-
ple collection. Platelet aggregation was initiated by 
using arachidonic acid (AA) ASPI test 0.5 mmol, 
thrombin receptor activating peptide (TRAP) test 
32 µmol, and ADP test 6.5 µmol, using reagents 
supplied by the manufacturer instructions (Roche/ 
/Dynabyte, Munich, Germany).
Statistical analyses
Plasma Cat-S and TSP-1 were compared in 
the two categorized groups and with controls. 
Non-parametric ANOVA test (Kruskal-Wallis) 
followed by Dunn’s multiple comparison test or 
Wilcoxon-Mann-Whitney test were used. Statisti-
cal significance was assumed when p < 0.05 was 
obtained. Correlations were analyzed using the 
Spearman test. 
Results
Cat-S and TSP-1 in STEMI patients
In STEMI patients, analyses of plasma levels 
of Cat-S and TSP-1 were conducted at three time-
points; acute (prior to PCI), 1–3 days after PCI 
and 3 months after PCI. When compared to sample 
analysis from healthy individuals, plasma Cat-S was 
almost 10-fold higher during acute STEMI and 1–3 
days after PCI (mean values ± standard deviation: 
42807 ± 11285, 31988 ± 7748 vs. 5071 ± 1003 pg/L). 
Analyses 3 months after PCI revealed that plasma 
Cat-S was slightly higher in samples from STEMI 
patients compared to control samples (8937 ± 1706 
vs. 5071 ± 1003 pg/L). Plasma TSP-1 was sig-
nificantly higher during acute STEMI compared to 
control levels (29448 ± 26089 vs. 16428 ± 10285 
ng/mL). On the other hand, plasma TSP-1 analyzed 
1–3 days and 3 months after PCI was substantially 
lower compared to control (4912 ± 11551, 3123 ± 
± 4441 vs. 16428 ± 10285 ng/mL). Cat-S did not cor- 
relate with TSP-1 prior to and after PCI (r = –0.153, 
p = 0.11 prior PCI; r = 0.099, p = 0.33 1–3 days 
after PCI; r = 0.104, p = 0.486 3 months after PCI).
Table 1. Demographic and clinical features of the patients at admission.
Subjects closed blood vessel Subjects open blood vessel
Number of subjects 90 40
Age [years] 71 [46-96] 68 [43–93]
Sex M/F 68/22 25/15
BMI [kg/m2] 27.3 [16.0–38.3] 27.3 [20.0–45.3]
Smoker 62% 60%
Previous MI 12% 20%
Diabetes mellitus 17% 20%
Hyperlipidemia 51% 40%
PCI [h] 0.11 [90] 0.15 [40]
PPT 224 228
WBC 13.5 10.1
Creatine kinase 82.8 83
Data are presented as mean values ± standard deviation. F — female; M — male; BMI — body mass index; MI — myocardial infarction;  
PCI — percutaneous coronary intervention; PPT — platelet particle concentration; WBC — white blood cell count
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STEMI patients with open  
and closed culprit vessels
For more detailed data analyses, patients were 
categorized into two groups, one with patent culprit 
vessel (n = 40) while the other group had closed 
culprit vessel (Table 1). Significant differences of 
baseline characteristics were found in hyperlipi-
demia, previous myocardial infarction and white 
blood cell count (p < 0.05). Plasma troponin I was 
analyzed as a biomarker of myocardial tissue injury. 
During the acute phase of STEMI (prior to PCI) 
there were no significant differences between the 
two patient groups (p = 0.087). However, after PCI 
intervention, troponin-I were significantly higher 
in patients with complete vessel occlusion (Fig. 1).
There were no significant differences in plas-
ma Cat-S between the groups with respectively, 
open and closed culprit lesion in blood samples 
drawn before and shortly after PCI (Fig. 2). Analy-
ses of samples obtained 3 months after PCI showed 
significantly lower Cat-S levels in both groups. 
However, plasma Cat-S was significantly higher 
(p < 0.001) in patient with closed culprit lesion 
(Fig. 2). Furthermore, in both patient groups 
(closed/open culprit lesions) plasma Cat-S 3 months 
after STEMI was significantly higher compared to 
samples from healthy individuals (p < 0.001). 
Platelet-specific TSP-1 plasma levels are 
shown in (Fig. 3). Similar to Cat-S, patient plasma 
analyses were conducted at three time-points; 
acute, 1–3 days after PCI and 3 months after PCI. 
As shown in (Fig. 3), plasma TSP-1 was high during 
the acute phase of STEMI but decreased signifi-
cantly (p < 0.001) in blood samples drawn 1–3 days 
after PCI. There were no significant differences 
in patient TSP-1 in samples obtained 1–3 days 
compared to 3 months after PCI. Furthermore, no 
significant differences in plasma TSP-1 between 
patients with open and closed culprit lesions were 
detected (p = 0.860 prior to PCI; p = 0.396 shortly 
after PCI; p = 0.944 3 months after PCI). Notably, 
TSP-1 in healthy individuals were significantly 
higher compared to patient samples both 1–3 days 
and 3 months after PCI. 
Platelet aggregation ex vivo was analyzed 
by measuring the increased impedance in whole 
blood samples. Analyses of blood samples drawn 
during the acute phase of STEMI revealed that the 
magnitude of ADP- and PAR-1 hexapeptide agonist 
SFLLRN-induced platelet aggregation were almost 
identical to that obtained from healthy volunteers 
(Fig. 4A, B). On the other hand, AA-induced 
platelet aggregation was significantly lower in 
the patient samples (p < 0.001; Fig. 4C). Platelet 
aggregation responses measured 1–3 days after 
PCI were substantially reduced in blood samples 
stimulated by AA, ADP and SFLLRN. It should be 
emphasized that patients underwent prehospital 
medication with acetylsalicylic acid (ASA), and, 
moreover, patients received a bolus dose of 300 mg 
clopidogrel. This pharmacological intervention 
most likely has a major impact on the efficiency of 
platelet activators in ex vivo aggregation measure-
ments. Despite this, no significant differences in 
platelet responsiveness between patients with 
open and closed culprit lesions were detected in 
any of the sampling times. 
Discussion
ST-segment elevation myocardial infarction 
is most often the result of complete or partial oc-
clusion of a major epicardial coronary vessel that 
must be diagnosed and treated promptly via coro-
nary revascularization by PCI [16, 17]. It has been 
observed that patients suffering from non-STEMI 
but with occluded culprit lesion have higher degree 
of hypercholesterolemia, more complex coronary 
disease and left ventricle (LV)-dysfunction [18], 
Figure 1. Plasma troponin-I during ST-segment eleva-
tion myocardial infarction. Troponin-I levels were ana-
lyzed in blood samples obtained before and shortly 
(1–3 days) after percutaneous coronary intervention 
(PCI) from patients with open and closed culprit lesion. 
Statistical analyses were conducted using the Mann- 
-Whitney U test (p < 0.01) and data are shown as me-
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and it is known that STEMI patients with occluded 
culprit lesion have a significant higher mortality 
rate than patients with open culprit lesion. Many 
mechanisms have been implicated in the forma-
tion of unstable atherosclerotic plaques leading to 
STEMI. For instance, it is believed that the activity 
Figure 2. Plasma cathepsin S (Cat-S) in ST-segment elevation myocardial infarction patients. Cat-S levels were ana-
lyzed in blood samples obtained before (I), 1–3 days after (II) and 3 months after (III) percutaneous coronary interven-
tion from patients with open/closed culprit lesion and healthy individuals (Ctrl). Statistical analyses were conducted 
by using Kruskal-Wallis followed by Dunn’s multiple comparison test (p < 0.001) and data are shown as median and 
5th–95th percentile; NS — non significant.
Figure 3. Plasma trombospondin-1 (TSP-1) in ST-segment elevation myocardial infarction patients. TSP-1 levels 
were analyzed in blood samples obtained before (I), 1–3 days after (II) and 3 months after (III) percutaneous coro-
nary intervention from patients with open/closed culprit lesion and healthy individuals (Ctrl). Statistical analyses 
were conducted by using Kruskal-Wallis followed by the Dunn’s multiple comparison test (*p < 0.05, **p < 0.01, 
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of the protease Cat-S is increased in the progress of 
atherosclerotic plaque with higher risk of rupture 
and uncontrolled platelet activation [19–22]. In this 
investigation, it was found that plasma Cat-S and 
platelet-specific TSP-1 was high during the acute 
phase of STEMI, but no significant differences were 
observed between patient groups with closed or 
open culprit lesion. However, in long time follow-
up analyses, plasma Cat-S (but not TSP-1) was 
significantly higher in patient with more severe 
STEMI (i.e. patient with closed culprit lesion). 
The involvement of Cat-S in atherosclerotic 
plaque rupture leading to platelet activation, throm-
bus formation and ultimately STEMI are not well 
studied. It is however believed that cathepsins may 
contribute to extracellular matrix damage which 
Figure 4. Platelet whole blood aggregation. Platelet aggregation responses in blood samples obtained before and 
1–3 days after percutaneous coronary intervention (PCI) from patient with open and closed culprit lesion. Aggregation 
was induced by ADP (A), the PAR-1-AP SFLLRN (B), and AA (C) and is expressed as area under curve (AUC). Platelet 
aggregation in control samples (healthy volunteers [Ctrl]) was analyzed in parallel. Statistical analyses were conducted 
by using Kruskal-Wallis followed by the Dunn’s multiple comparison test (p < 0.001) and data are shown as median 
and 5th–95th percentile; NS — non significant.
precedes atheroma rupture [6, 9]. In the present 
study, it was found that plasma Cat-S was high prior 
to PCI. This may indicate that analysis of Cat-S may 
be useful for evaluating patients with vulnerable 
plaques; patients with high risk of acute infarction. 
It is to be noted that Cat-S was only marginally 
reduced at days 1–3 post-PCI; a more significant 
reduction was observed 3 months post-PCI. This 
is in contrast to registered TSP-1 levels which re-
turned to low levels shortly after PCI. It is possible 
that Cat-S remains higher as a result of ischemia 
reperfusion injury leading to e.g. endothelial cell 
activation. In accordance with our findings, Cat-S 
has been implicated in acute infarction and severe 
coronary vessel atherosclerosis in human atheroma 




















































































































p < 0.001 p < 0.001




Rahel Befekadu et al., Increased plasma cathepsin S and trombospondin-1 in patients with acute STEMI
reflects ongoing inflammation associated with 
severe coronary atherosclerosis. It has also been 
proposed that Cat-S is released during ischemic 
necrosis following MI [24]. Furthermore, Cat-S has 
been linked to disease severity and is associated 
with increased mortality risk in different diseases 
[23, 25]. Interestingly, in the present long-term 
follow-up analysis, it was found that plasma Cat-S 
was significantly higher in patient with closed 
culprit lesion. This may be the result of a more 
extensive myocardial ischemia/reperfusion injury 
following complete occlusion of coronary vessel. 
In accordance with this, the present data showed 
that troponin-I levels were significantly higher 
in the group with closed culprit lesion. Taken 
together, it may be speculated that a rise in Cat-S 
may precede a thrombotic event whereas TSP-1 
levels rise sharply following uncontrolled platelet 
activation. In accordance to this, it was recently 
shown that Cat-S levels were higher in stable as 
well as unstable CAD compared to healthy controls 
[26]. However, the significance of Cats-S and TSP-1 
analyses in CADs that precede STEMI remains to 
be elucidated.
Trombospondin-1 is stored within platelet 
alpha-granules, from which it is quickly released 
during platelet activation, and may thus be a suit-
able biomarker indicative for uncontrolled platelet 
activation initiating artery thrombosis. TSP-1 
acts as an extracellular matrix glycoprotein that 
influences cell adhesion, motility, and increases 
endothelial cell proliferation [27]. In this study it 
was observed that plasma TSP-1 rapidly declined 
far below basal, physiological levels (compared 
to healthy individuals). This took place during 
the first 72 h which indicates that TSP-1 may be 
useful as a marker of the most acute phase of MI, 
i.e. systemic biomarker in plasma indicative for 
misdirected platelet activation in coronary vessels. 
On the other hand, TSP-1 analysis is not useful for 
long-term follow-up analyses. The pharmacological 
intervention of the patients is probably the reason 
for low TSP-1 compared to the healthy control 
population. Interestingly, ex vivo analyses of ag-
gregation revealed that platelets obtained from 
patients respond in a normal manner (as healthy 
individual) to ADP and the thrombin mimetic hexa-
peptide agonist SFLLRN during the acute phase of 
STEMI (the blood sample drawn prior to PCI). This 
implies that platelet functional tests even at acute 
and severe cardiovascular disease shed no light on 
platelet dysfunctionality following plaque rupture 
and arterial thrombus formation. A significant de-
crease in platelet aggregation was noticed in patient 
samples stimulated with AA (prior/after PCI), ADP 
(after PCI) and (to lesser extent) SFLLRN (after 
PCI). This is most likely caused by pharmacological 
interventions of the patients. In accordance, it has 
previously been shown that pre-hospital medica-
tion with 300 mg ASA caused a 50% reduction in 
platelet aggregation using AA stimulation whereas 
anti-platelet effect of clopidogrel was observed 
after 72 h [28]. The rapid effect of ASA is expected 
based on the known pharmacokinetics of ASA and 
the ISIS-2 study published three decades ago that 
showed a beneficial effect of platelet inhibition 
[29, 30]. Clopidogrel is metabolized by a two-step 
mechanism to acquire the active metabolite that 
inhibits platelet P2Y12 receptors. In this study, 
a loading dose of 300 mg clopidogrel was used. This 
may explain the modest effect on platelets stimu-
lated by ADP. In comparison, other studies have 
shown that a higher loading dose (600 mg) induces 
a more rapid and significantly better effect of the drug 
[28]. The time from medication with clopidogrel to 
the arrival at the catherization laboratory was ap-
proximately 80 min. Furthermore, it is known that 
more than 20% of the population are not capable of 
a second metabolization due to a heritable defect 
in the enzyme [31]. Collectively, this may explain 
the relatively weak effect of the P2Y12 inhibitor in 
ex vivo aggregation analyses. Activation of platelet 
by the thrombin mimetic hexapeptide SFLLRN was 
marginally affected by ASA and clopidogrel treat-
ments. This is probably explained by the efficiency of 
thrombin receptors in inducing intracellular signaling 
[32]. Specifically, this means that thrombin activation 
of platelets does not rely on secondary positive feed-
back loops such as thromboxane A2 and ADP. Overall, 
it was concluded that platelet aggregation ex vivo did 
not provide useful information in STEMI with closed 
or open culprit lesions.
In summary, the present results show sig-
nificantly elevated levels of TSP-1 (indicative of 
platelet activation) and Cat-S during the acute 
stage of STEMI. No significant differences were 
observed between patients with closed culprit 
lesion as compared to patients with open culprit 
lesion during and after management of STEMI. 
However, from a long term perspective, high 
plasma Cat-S was associated with more severe 
STEMI characterized by closed culprit lesion and 
higher troponin-I. Long term analyses of TSP-1 and 
platelet aggregation measurement sheds no light 
on inappropriate platelet activation during STEMI. 
Analyses of platelet-specific granule constituents 
like TSP-1 may be a valuable diagnostic tool during 
the acute stage of the disease.  
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Conclusions
Cathepsin S and trombospondin-1 levels are 
high during acute STEMI and this may contribute 
to new knowledge related to foregoing plaque rup-
ture. Elevated levels of Cat-S months after STEMI 
may reflect the severity of the heart disease and 
may be important for prognosis. Low levels of 
TSP-1 already 1–3 days after STEMI probably 
reflects the pharmacological interventions of the 
patients. Future studies with larger patient groups 
may reveal the causality of Cat-S as a biomarker in 
myocardial infarction.
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